Y-MABS THERAPEUTICS, INC.

(YMAB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Y-MABS THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)

12/15/2021 | 09:29am EDT

Item 8.01. Other Events

On December 15, 2021, Y-mAbs Therapeutics, Inc., (the "Company") issued a press release announcing a pipeline update to be presented at the Company's R&D event, which takes place virtually at 12 p.m. Eastern Time on December 15, 2021. A copy of the press release is attached hereto as Exhibit 99.1.

The information furnished pursuant to Item 8.01 on this Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.



(d) Exhibits



Exhibit No.   Description

  99.1          Press Release, dated December 15, 2021 issued by Y-mAbs
              Therapeutics, Inc.

104           Interactive Data File (embedded within the Inline XBRL document).

© Edgar Online, source Glimpses

All news about Y-MABS THERAPEUTICS, INC.
05/26Y MABS THERAPEUTICS : mAbs Announces Naxitamab Chemoimmunotherap Investigational Trial for..
PU
05/26Y-MABS THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
05/26Y-mAbs Phase 2 Trial of Naxitamab Chemoimmunotherapy for High-Risk Neuroblastoma Achiev..
MT
05/26Y-mAbs Announces Naxitamab Chemoimmunotherapy Investigational Trial for High-Risk Neuro..
AQ
05/26Y-mAbs Therapeutics, Inc Announces Naxitamab Chemoimmunotherapy Investigational Trial f..
CI
05/19Y-mAbs Therapeutics Appoints President Thomas Gad Interim CEO
MT
05/19Y-MABS THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
05/10Wedbush Adjusts Price Target for Y-mAbs Therapeutics to $21 From $28, Maintains Outperf..
MT
05/10TRANSCRIPT : Y-mAbs Therapeutics, Inc., Q1 2022 Earnings Call, May 10, 2022
CI
05/09Y-MABS THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition ..
AQ
More news
Analyst Recommendations on Y-MABS THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 63,4 M - -
Net income 2022 -89,4 M - -
Net cash 2022 197 M - -
P/E ratio 2022 -5,77x
Yield 2022 -
Capitalization 510 M 510 M -
EV / Sales 2022 4,93x
EV / Sales 2023 3,59x
Nbr of Employees 148
Free-Float 87,7%
Chart Y-MABS THERAPEUTICS, INC.
Duration : Period :
Y-mAbs Therapeutics, Inc. Technical Analysis Chart | YMAB | US9842411095 | MarketScreener
Technical analysis trends Y-MABS THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 11,66 $
Average target price 27,83 $
Spread / Average Target 139%
EPS Revisions
Managers and Directors
Thomas Gad President & Chief Executive Officer
Bo Kruse CFO, Secretary. Treasurer & Executive VP
James Irvin Healy Chairman
Torben Lund-Hansen Chief Technology Officer & Senior Vice President
Steen Lisby Chief Scientific Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
Y-MABS THERAPEUTICS, INC.-28.07%510
GILEAD SCIENCES, INC.-10.76%81 280
REGENERON PHARMACEUTICALS, INC.9.70%74 647
VERTEX PHARMACEUTICALS24.65%70 008
BIONTECH SE-35.24%40 574
WUXI APPTEC CO., LTD.-22.01%39 958